Korean Medication Algorithm Project for Depressive Disorder 2021 (IV): Female and Elderly
10.4306/jknpa.2021.60.4.258
- Author:
Sheng-Min WANG
1
;
Won-Myong BAHK
;
Young Sup WOO
;
Jeong Seok SEO
;
Young-Min PARK
;
Won KIM
;
Jong-Hyun JEONG
;
Se-Hoon SHIM
;
Jung Goo LEE
;
Seung-Ho JANG
;
Chan-Mo YANG
;
Myung Hun JUNG
;
Hyung Mo SUNG
;
IL Han CHOO
;
Bo-Hyun YOON
;
Sang-Yeol LEE
;
Duk-In JON
;
Kyung Joon MIN
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Korean Neuropsychiatric Association
2021;60(4):258-266
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:An expert consensus guideline for the treatment of depressive disorder, the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD), was first established in 2002 and updated in 2017. To provide an up-to-date treatment guideline, KMAP-DD 2021 was recently completed. This study was undertaken to provide a guideline for the treatment of depressive disorder in a selected population that included females and elderly.
Methods:The survey conducted consisted of 7 questionnaires for each population, females and elderly, with depressive disorder. A total of 65 of 97 experienced psychiatrists answered the survey.
Results:For the treatment of premenstrual dysphoric disorder, the selective serotonin reuptake inhibitors, venlafaxine, and desvenlafaxine were recommended as first-line therapies. For major depressive disorder (MDD) during pregnancy, antidepressant (AD) monotherapy was recommended as a first-line therapy for mild to moderate and severe depression, and combined electroconvulsive therapy and AD with atypical antipsychotics (AAP) were recommended as a first-line therapy for severe depression with psychotic features. AD plus AAP was generally recommended for post-partum depression. In elderly with depression, AD monotherapy was recommended as the treatment of choice for mild to moderate episodes, and AD monotherapy and AD plus AAP were recommended as a first-line therapy for severe depression without psychotic features. Lastly, AD plus AAP was chosen as the treatment of choice for psychotic depression.
Conclusion:Present study provides an updated algorithm for the treatment of females and elderly with depressive disorders. This algorithm provides a practical aid to clinicians for the treatment of females and elderly with MDD.
